Previous close | 160.40 |
Open | 160.71 |
Bid | 160.11 x 800 |
Ask | 161.22 x 1000 |
Day's range | 160.35 - 161.44 |
52-week range | 130.96 - 182.89 |
Volume | |
Avg. volume | 5,658,393 |
Market cap | 283.864B |
Beta (5Y monthly) | 0.59 |
PE ratio (TTM) | 47.84 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 6.20 (3.86%) |
Ex-dividend date | 12 Apr 2024 |
1y target est | N/A |
AbbVie (NYSE: ABBV) announced today that Health Canada has approved QULIPTA (atogepant) for the prevention of migraine in adults who have at least four migraine days per month.1 QULIPTA is the first and only oral, small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) approved to prevent both episodic and chronic migraine.
AbbVie (NYSE: ABBV) will participate in the Bank of America Securities Healthcare Conference on Wednesday, May 15, 2024. Robert A. Michael, president and chief operating officer, Scott T. Reents, executive vice president, chief financial officer, Jeffrey R. Stewart, executive vice president, chief commercial officer and Roopal Thakkar, M.D., senior vice president, chief medical officer, global therapeutics, will present at 12:40 p.m. Central time.
AbbVie (NYSE:ABBV) announced financial results for the first quarter ended March 31, 2024.